Additionally, the combination of dapagliflozin and metformin treatment significantly reduced PRAT layers in obese patients with type 2 diabetes, accompanied by reductions in plasma leptin, C-reactive protein, and urinary microalbumin levels (43). The gene discussed is LEP; the disease is type 2 diabetes mellitus.